Is Molecular Psychiatry a Good Journal? Impact Factor, Scope, and Fit Guide

Molecular Psychiatry's editorial bar has shifted over the past five years. Early in the GWAS era, a well-powered genome-wide association study with psychiatric phenotypes was enough. Today, the journal expects papers to go further: from association to mechanism, from mechanism toward clinical relevance. This does not mean every paper needs a clinical trial component. It means the biological interpretation has to be substantive rather than a concluding paragraph that gestures toward "future translational work."

In practice, the strongest Molecular Psychiatry papers combine at least two levels of evidence. A GWAS paper that also includes functional genomics, gene expression data, or cellular validation. A neuroimaging study that also ties activation patterns to genetic variation or treatment response. A pharmacogenomics paper that connects genotype to drug metabolism and clinical outcomes. The single-modality paper with speculative translational implications is a harder sell than it was five years ago.

1. Multi-level evidence: the paper connects genetic variants to expression changes to cellular phenotypes, or connects imaging patterns to genetic risk to clinical outcomes
2. Psychiatric specificity: the biology is clearly about a psychiatric disorder, not generic brain science that mentions depression in the discussion
3. Adequate power: sample sizes match the effect sizes being claimed, whether for GWAS, imaging, or clinical studies
4. Functional interpretation: statistical associations are followed by biological explanation rather than left as "further work is needed"
5. Translational credibility: the clinical implications are stated carefully and are proportional to the evidence, not inflated beyond what the data support

What is the Molecular Psychiatry impact factor?

The 2024 JCR impact factor is 10.1, with a 5-year IF of 11.8 and a JCI of 2.21. Molecular Psychiatry ranks Q1 in Psychiatry (7th of 288 journals) and is published by Nature Portfolio. It is one of the leading venues for research connecting molecular and genetic mechanisms to psychiatric disorders and treatment.

What is the Molecular Psychiatry acceptance rate?

Approximately 10-15%. The journal is highly selective and requires manuscripts that bridge biological mechanism with psychiatric clinical relevance. Pure association studies without functional interpretation are frequently desk-rejected.

How does Molecular Psychiatry compare to Biological Psychiatry?

Molecular Psychiatry (IF 10.1) and Biological Psychiatry (IF 9.6) occupy similar territory. Molecular Psychiatry (Nature Portfolio) tends toward larger genetic and multi-omics studies and has historically been the default venue for large psychiatric GWAS papers. Biological Psychiatry (Elsevier, linked to SOBP) is somewhat more circuit- and pharmacology-oriented. The difference is editorial culture more than scope.

What types of papers does Molecular Psychiatry publish?

The journal publishes psychiatric genetics and genomics (GWAS, polygenic scores, rare variants), neuroimaging studies with psychiatric relevance, molecular and cellular mechanisms of psychiatric disorders, pharmacogenomics and treatment response biomarkers, and translational studies connecting animal models to human psychiatric phenotypes.

In our pre-submission review work with manuscripts targeting Molecular Psychiatry, three patterns generate the most consistent desk rejections among the papers we analyze.

Association findings presented without functional mechanism. Molecular Psychiatry's editorial guidelines state that the journal prioritizes research connecting molecular and biological mechanisms to psychiatric disorders. We see a consistent pattern where GWAS or imaging studies identify a statistical association with a psychiatric phenotype and then stop. The abstract claims the finding is "the first to link X to Y" without any functional interpretation of what the biology means for disease mechanism or treatment. The editor's desk decision framework asks whether the paper advances understanding of biological mechanism, not just statistical association. Papers that are association-only without functional follow-through are returned before external review with increasing frequency as the field has moved toward requiring mechanistic interpretation.

Translational bridge missing between model systems and clinical phenotypes. The journal expects papers using animal models or cell systems to explicitly justify the translational relevance to human psychiatric disease. We observe that papers using mouse behavioral assays or iPSC-derived neurons frequently present the biological findings without connecting them to specific psychiatric phenotypes, treatment response variability, or patient subgroups. Molecular Psychiatry's scope description references "the interface of molecular medicine and psychiatry," and reviewers from the clinical psychiatry side of the reviewer pool specifically assess whether the mechanistic findings are interpretable in terms of clinical reality. Papers that cannot make this connection explicitly are redirected to basic neuroscience journals.

Sample size insufficient for the GWAS-era expectation. Molecular Psychiatry has published many of the field-defining psychiatric genetic studies, and the editorial team is calibrated to large-N genomic research. We see candidate gene studies or small-cohort neuroimaging papers submitted with n=50-200 that cannot replicate or generalize. The journal's historical appetite for large GWAS papers has raised the bar for what counts as a sufficient sample for genetic claims. Small studies need strong mechanistic or functional data to compensate for sample limitations, and papers that do not address this limitation explicitly are rejected at review on statistical power grounds.

SciRev author-reported data confirms Molecular Psychiatry's 6-10 week median to first decision. A Molecular Psychiatry translational framing and sample size check can assess whether your translational framing, mechanistic interpretation, and sample size justification are positioned for Molecular Psychiatry's editorial standard before submission.